Elicio Therapeutics (ELTX) Total Non-Current Liabilities (2021 - 2026)

Elicio Therapeutics (ELTX) has reported Total Non-Current Liabilities for 6 consecutive years, with $22.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Non-Current Liabilities fell 6.69% year-over-year to $22.3 million; the trailing twelve-month figure through Jun 2026 stood at $22.3 million (down 6.69% YoY), and the FY2025 full-year result was $21.6 million, down 41.05% from the prior year.
• Total Non-Current Liabilities climbed to $22.3 million in Q2 2026 per ELTX's latest filing, from $20.5 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $36.7 million in Q4 2024 and bottomed at $11.0 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $20.1 million across 5 years, with a median of $20.5 million in 2026.
• The sharpest annual moves came in 2024 and 2025: Total Non-Current Liabilities jumped 132.6% in 2024, then sank 41.05% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $11.0 million in 2022, then jumped by 43.66% to $15.8 million in 2023, then surged by 132.6% to $36.7 million in 2024, then tumbled by 41.05% to $21.6 million in 2025, then rose by 3.08% to $22.3 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $22.3 million, $20.5 million, and $21.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.